A study of high-sensitivity C- reactive protein and trop-T in patients with coronary artery disease

Anita Rathore, Umesh Pareek, Avdhesh Sharma


Background: The diagnosis of Hs-CRP levels is helpful to correlate with the clinical severity of coronary artery disease and with coronary events in both acute and sub-acute phase of myocardial ischemia. Coronary heart disease (CHD) is the major cause of death in the developed world. The level of certain proteins in plasma increase during acute inflammatory state or secondary to certain types of tissue damage.

Methods: 100 subjects and 50 controls were taken from the outdoor and indoor department of medicine in Geetanjali Medical College & Hospital, Udaipur, Rajasthan, India. C-reactive protein was estimated by immuno-turbidometry method.

Results: We have also come across very high levels of Hs-CRP in the CAD patients and found that the value of Hs-CRP was 2.51±0.79 mg/L as compared to 0.76±0.34 mg/L in control and therefore the rise in Hs-CRP is highly significant because of p value (0.0001).

Conclusions: Hs-CRP is highly significant in CAD patients when compared to the control group. It is an independent and better predictor of CAD.


CAD, HS-CRP, Troponin -T, Inflammation

Full Text:



Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation 1999;100:1148-50.

Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26.

Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-50.

Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mono- nuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788-91.

Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 1999;100:713-6.

Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estro-gen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717-22.

Kapyaho K, Welin MG, Tanner P, Karkkainen T, Weber T. Rapid determination of C-reactive protein by enzyme immunoassay using two monoclonal antibodies. Scand J Clin Lab Invest. 1989;49:389-93.

Kervinen H, Palosuo T, Maninnen V, Tenkanen L, Vaarala O, Mänttäri M. Joint effect or C-reactive protein and other risk factors on acute coronary syndrome. Am Heart J. 2001;141:580-5.

Katritis D, Korovesis S, Giazitizoglou E, Parissis J, Kalivas P, Webb-Peploe MM et al. C-Reactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem. 2000;47:882-6.

Patel VB, Robbins MA, Topol EJ. C-reactive protein: A golden marker’ for inflammation and coronary artery disease. Cleveland Clinic J of Medicine. 2001;6(68):521-34.

Hull SK. How useful is high-sensitivity CRP as a risk factorfor coronary artery disease? J of Family Practice. 2005;54(3):268-9.

Koenig W, Sund M, Fröhlich M, Fischer H, Löwel H, Döring AA, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation.1999;99:237-42.